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Over the last decade, the number of disease-modifying treat-
ments (DMTs) available to patients with multiple sclerosis 
(MS) has exponentially increased in number. For clinicians 
equipped with this armamentarium, who and when to treat to 
maximise therapeutic efficacy, whilst being ever mindful of 
potential serious side effects has become a focus of routine 
clinical practice.
With the severity of the MS clinical phenotype ranging 
so widely from benign to aggressive disease, the ability 
of a clinician to be able to make an accurate forecast of 
a patient’s disease trajectory is of great value. Stratifying 
patients based on available clinical and radiological data 
allows an informed decision to be made about the intensity 
of disease surveillance and the balance of risk and benefits 
of different therapeutic agents. However, this is an imprecise 
science and further studies aiding understanding of this are 
to be welcomed. Once a diagnosis is made, early treatment 
with immunosuppressive or immunomodulating therapies is 
increasingly favoured to prevent future episodes of neuroin-
flammation and disability accumulation in the longer term. 
As such, any novel methods to detect and diagnose disease 
at an earlier stage are an area of keen interest to neurologists 
working in this field.
In this months’ journal club, we consider three papers 
whose aim is to aid earlier diagnosis and predict disease 
development and trajectory. First, Outteryck and colleagues 
investigate the use of optical coherence tomography in aid-
ing the detection of both symptomatic and asymptomatic 
optic nerve lesions in patients with clinically isolated syn-
drome. This technique may have clinical utility where opti-
mal radiological imaging is unavailable for the detection of 
optic nerve lesions and potentially in the development of 
future MS diagnostic criteria. In the second paper, Lebrun-
Frenay et al. evaluate the 10-year risk of a clinical event 
following a diagnosis of radiologically isolated syndrome 
(RIS). This large cohort study is informative for both clini-
cians and patients alike in understanding future develop-
ment of disease. In the third paper, the MSBase study group 
identify early clinical markers of aggressive MS develop-
ment and reveal easily accessible parameters to help identify 
such patients. These studies will help clinicians in evaluating 
the risk of MS disease development and subsequent disease 
progression. In turn, this will inform predictions of disease 
trajectory, aid patient counselling and inform individual 
management decisions.
Optical coherence tomography for detection 
of asymptomatic optic nerve lesions 
in clinically isolated syndrome
Optic nerve lesions are commonly encountered as part of 
the clinically isolated syndrome (CIS). Despite this, they 
are not considered as part of the criteria to identify dissemi-
nation in space (DIS). Inclusion in these criteria may be 
of potential clinical utility in identifying DIS at an earlier 
stage. Optical coherence tomography (OCT)—and in par-
ticular, the intereye retinal thickness difference (IETD)—is 
a potentially sensitive modality to study optic nerve lesions. 
This study aimed to evaluate the diagnostic accuracy of the 
IETD in a cohort of patients with CIS for both symptomatic 
and asymptomatic optic nerve lesions.
One hundred and thirty patients with a CIS in the previ-
ous 2.5–4.5 months were prospectively recruited. Demo-
graphic and clinical data were collected with each patient 
undergoing a 3 T MRI brain scan (3D-DIR sequence) and 
OCT on the same day. For each optic nerve, the presence or 
absence of DIR hypersignal was recorded. All patients had 
typical MS lesions outside of the optic nerve. According to 
the 2017 McDonald criteria, characteristics for DIS were 
fulfilled for 117 patients and dissemination in time (DIT) for 
112. In total, 105 patients fulfilled MS diagnostic criteria. 
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A clinical episode of unilateral ON occurred in 37 patients 
and bilateral ON in 2 patients. Two groups of patients were 
subsequently defined: patients with ON (CIS-ON) and with-
out ON (CIS-NON).
In the CIS-ON group (n = 39), imaging demonstrated 
DIR hypersignal in all 41 symptomatic optic nerves and in 
11 asymptomatic optic nerves. Imaging of the CIS-NON 
group (n = 91) demonstrated unilateral optic nerve lesions 
in 22 patients and bilateral optic nerve hypersignal in 7 
patients. Retinal thickness/volume was significantly lower 
in eyes with symptomatic lesions vs. asymptomatic lesions 
or vs. eyes without optic nerve lesions. Similarly, eyes with 
asymptomatic optic nerve lesions had lower retinal thick-
ness/volume than eyes without optic nerve lesions. CIS-ON 
patients had greater IETD difference compared to CIS-NON 
patients. For the detection of symptomatic and asymptomatic 
optic nerve lesions, ganglion cell layer coupled to the inner 
plexiform layer (GC-IPL) IETD had better performance as 
compared to peripapillary retinal nerve fiber layer (pRNFL) 
IETD.
Comment: This study confirmed a high frequency of 
asymptomatic optic nerve lesions and that GC-IPL IETD 
was the most accurate measure in detecting both asympto-
matic and symptomatic lesions. Thresholds for identifying 
optic nerve lesions were lower than previously reported. The 
results of this study suggest that IETD may be a potential 
biomarker for identifying optic nerve lesions. This may aid 
future longitudinal studies, evaluating whether inclusion of 
optic nerve lesions in the next iteration of the diagnostic 
criteria is warranted. This test may also have clinical utility 
where sensitive MRI detection of optic nerve lesions is una-
vailable. However, as this study was performed on a single 
OCT machine and clinical cohort (CIS), the results may not 
be applicable to all OCT machines and other MS disease 
states.
Outteryck et al. (2020) Neurology 95(6):e733–e744. https 
://doi.org/10.1212/WNL.00000 00000 00983 2 (Epub 2020 
Jul 28)
Radiologically isolated syndrome: 10‑year 
risk estimate of a clinical event
Radiologically isolated syndrome (RIS) describes brain MRI 
findings incidentally fulfilling the criteria for dissemination 
in space (DIS), but without any clinical correlate of inflam-
matory disease. Although important to recognise through 
accurate radiological reporting and detailed history taking, 
the long-term risk of developing a clinical event is unknown 
and there are no guidelines for surveillance or treatment. This 
study group (who have previously reported on the 5-year 
risk) therefore aimed to estimate the risk of a clinical event 
(either an acute demyelinating event or 12 month in symptom 
progression) at 10 years. In addition, the association of this 
risk with baseline demographic, clinical and radiological char-
acteristics was investigated.
This study included the 451 patients from the authors’ 
original 2014 cohort. All baseline scans fulfilled the 2009 cri-
teria for RIS (2005 criteria for DIS). Demographics, family 
history, clinical data, neurological examination results, brain 
and cord MRI findings and CSF were collected at baseline. 
Patients were followed longitudinally with standardised clini-
cal assessments and MRI performed as per clinical care. The 
current study obtained data on events that occurred subsequent 
to 2014—these data were used where available (277 patients, 
61.4%), otherwise original data were used.
Of the 451 patients, 86.5% were female with a mean age 
at RIS diagnosis of 37.2 years and median follow-up time of 
6.7 years (range 1–26.6 years). A large proportion of patients 
were treated with disease-modifying therapy (DMT): non-
updated patients, 18.2%; updated patients, 16.7%. Of the total 
cohort, 173 patients developed symptoms, 21 of which were 
deemed to be progressive. With regard to the total cohort, the 
cumulative probability of a first clinical event after 10 years 
following a diagnosis of RIS was 51.2%. When assessed as 
prognostic factors, age < 37 years, positive CSF (oligoclonal 
bands or high IgG index), spinal cord and infratentorial lesions 
were all independently associated with an increased 10-year 
risk to first clinical event. When assessed together, these four 
factors had a cumulative increase in risk with the presence of 
all four risk factors conveying an 87% risk. In addition, con-
trast enhancement on follow-up MRI was also significantly 
associated in the univariate analysis.
Comment: This large cohort study with long follow-up 
estimates the 10-year risk from RIS to first clinical event 
at 51.2% overall. Four key risk factors were identified—
younger age, a positive CSF profile, the presence of spinal 
cord or infratentorial lesions, and the occurrence of con-
trast enhancing lesions during follow-up. These results will 
inform clinicians and help guide discussions with patients. 
The authors, however, acknowledge a few limitations of this 
study such as the retrospective design, the variability in MRI 
scanners, the lack of an adjudication committee for clinical 
events, and incomplete follow-up for some patients. A high 
proportion of patients were also exposed to DMTs, which 
may have affected outcomes.
Lebrun-Frenay et al. (2020) Ann Neurol. https ://doi.
org/10.1002/ana.25799 . (Online ahead of print)
Early clinical markers of aggressive multiple 
sclerosis
With a wide spectrum of MS disease activity, the identifi-
cation of early clinical indicators for disease severity war-
rants close investigation to help guide surveillance and 
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management. In particular, the clinical predictors of aggres-
sive multiple sclerosis—whereby disability is accrued at an 
accelerated rate—are not well understood. This study, there-
fore, aimed to identify early clinical markers, present within 
the first year of disease, which would indicate an aggressive 
disease trajectory.
Patients were included in the study if the following cri-
teria were met: (1) a diagnosis of clinically definite relapse-
onset multiple sclerosis; (2) age at onset ≥ 18 years; (3) first 
EDSS recorded within 12 months of symptom onset; (4) at 
least two recorded EDSS scores within 10 years of symptom 
onset; and (5) at least 10 years of observation time. Patients 
were classified as having aggressive multiple sclerosis if 
they met all three of the following criteria: (1) EDSS ≥ 6 
within 10 years of symptom onset; (2) EDSS ≥ 6 confirmed 
and sustained over ≥ 6 months; and (3) EDSS ≥ 6 sustained 
until the end of follow-up (≥ 10 years).
Clinical predictors included patient variables (sex, age 
at onset, baseline EDSS, disease duration at first visit) and 
recorded relapses in the first 12 months since disease onset 
(count, pyramidal signs, bowel–bladder symptoms, cerebel-
lar signs, incomplete relapse recovery, steroid administra-
tion, hospitalization). For the initial analysis, patient data 
were obtained from the established international MSBase 
cohort and Bayesian methods, including Bayesian model 
averaging (BMA) were used to estimate the risk of aggres-
sive disease in individual patients. Following initial analysis, 
validation was performed in a second independent cohort 
(Swedish Multiple Sclerosis Registry).
From the MSBase cohort, 2403 patients met inclusion cri-
teria. Of these, 145 (6%) met criteria for aggressive disease. 
The mean time from disease onset to aggressive disease defi-
nition was 6.05 years. The strongest predictors for aggressive 
disease included older age at symptom onset (> 35 years) 
along with high EDSS (≥ 3) and the presence of pyrami-
dal signs in the first year of disease. When evaluated in the 
second independent cohort, the combination of these three 
signs was also predictive of aggressive disease. Conversely, 
the absence of these signs was associated with a lower risk 
of following an aggressive disease course.
Comment: This study identified clinically accessible 
markers that when identified in the first year since symp-
tom onset suggest an increased risk of an aggressive disease 
course. These results are of clinical importance, particularly 
for the identification of patients that will likely benefit from 
early, aggressive disease-modifying therapy. A limitation of 
the study included the relative lack of MRI and CSF data. 
The authors helpfully surmise that early clinical markers of 
aggressive disease are (1) median EDSS ≥ 3 (2) any pyrami-
dal signs on examination in the first year, and (3) age > 35 
at symptom onset.
Malpas et al. (2020) Brain 143(5):1400–1413. https ://doi.
org/10.1093/brain /awaa0 81
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